Supply Chain Archives
Industry Insights
03/19/2026
ATC 2026 Keynote Recap: Building Global Readiness for Advanced Therapies
Alison Pritchard, VP of Business Development – EMEA at Cryoport Systems, delivered the Keynote Address at the Advanced Therapies Congress 2026, grounding the discussion in the accelerating pace of global expansion across the cell and gene therapy industry. Clinical trials now commonly stretch across regions, and manufacturing networks are distributed in ways that require constant coordination. These patterns have become the norm rather than the exception. As she described it, the operating environment for advanced therapies has already become global, and every program is expected to function within that reality much earlier than in the past.
Managing the Cold Chain
02/26/2026
Building Investor Confidence Through an Intentional Supply Chain Strategy
In early investment conversations, scientific innovation used to carry most of the weight. A compelling mechanism of action, a clear unmet need, and solid early data together were enough to advance the discussion and give investors a sense of potential. In today’s funding environment, however, that has shifted. Today, investors quickly move past the science and begin investigating whether a program can operate with the discipline and scalability required to grow.
Managing the Cold Chain
02/18/2026
Build Standardization Where It Matters Most: Turning Stability into True Consistency
There is a quiet assumption that many early-phase teams make when they transition to cryopreserved starting material... that freezing alone will solve their variability problem. On the surface, it feels true. Cryopreservation stops the clock, stabilizes the cells, and removes the minute-to-minute fragility of fresh material. But the stability that teams expect isn’t guaranteed by freezing itself, it’s created by how the freezing is done. And in practice, this is where programs often get surprised.
Managing the Cold Chain
01/27/2026
Establish Stability from the Start with Frozen Starting Materials for Cell Therapy Development
For many years, cell therapy programs defaulted to fresh leukapheresis-derived starting material. The assumption was that if you could minimize the time from collection to manufacturing, you would maximize viability. As a result, fresh apheresis became not only a scientific preference but an operational tradition, shaping how clinical teams would schedule donors, how manufacturing suites would allocate capacity, and how programs would structure day-to-day execution. Program leaders treated any deviation from “fresh” as a risk to be justified rather than a choice to be evaluated. But reality keeps getting in the way.
Managing the Cold Chain
01/27/2026
How Defragmenting the Pre-Clinical Supply Chain De-Risks Downstream Operations
Every stage of the supply chain including cryopreservation, logistics, and BioServices and biostorage, must align to ensure a seamless transition from pre-clinical work into Phase I trials. However, early-stage teams often select multiple vendors who each handle one piece of the process because it feels faster or more cost-effective in the moment. This approach, however, builds fragmented supply chains that introduce gaps as programs scale. And when those gaps surface, teams must devote valuable time and effort simply to get back on track.
Managing the Cold Chain
10/15/2025
The Connected Chain: Why Supply Chain Integration Matters in Advanced Therapy Manufacturing
Contract Development and Manufacturing Organizations (CDMOs) are at the heart of the advanced therapy ecosystem, managing complex, high-stakes programs that demand speed and compliance. As therapies move from early development into clinical trials and through to commercialization, every stage of manufacturing, packaging, biostorage, and final drug delivery need to align perfectly for seamless execution. Yet in many cases, these functions are managed by multiple vendors, each operating in isolation. The result is a fragmented supply chain that increases risk while slowing execution due to layers of operational burden.
Supply Chain
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
Managing the Cold Chain
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
Managing the Cold Chain
08/20/2025